For investors seeking momentum, Loncar Cancer Immunotherapy ETF (CNCR - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 37.4% from its 52-week low price of $21.09/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
CNCR in Focus
This fund provides exposure to companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. CNCR charges 79 bps in fees per year from its investors (see: all the Healthcare ETFs here).
Why the Move?
The biotech segment of the broad equity market has been an area to watch lately, given encouraging industry fundamentals including mergers and acquisitions, earnings growth, promising drug launches, faster drug approvals, cost-cutting efforts, an aging population and Trump’s tax reform. In particular, the new tax legislation enticed companies to bring offshore cash back home, leading to a wave of mergers and acquisitions.
More Gains Ahead?
CNCR has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely still some promise for those who want to ride on this surging ETF a little longer.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For investors seeking momentum, Loncar Cancer Immunotherapy ETF (CNCR - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 37.4% from its 52-week low price of $21.09/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
CNCR in Focus
This fund provides exposure to companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that may have a foundational impact on cancer care. CNCR charges 79 bps in fees per year from its investors (see: all the Healthcare ETFs here).
Why the Move?
The biotech segment of the broad equity market has been an area to watch lately, given encouraging industry fundamentals including mergers and acquisitions, earnings growth, promising drug launches, faster drug approvals, cost-cutting efforts, an aging population and Trump’s tax reform. In particular, the new tax legislation enticed companies to bring offshore cash back home, leading to a wave of mergers and acquisitions.
More Gains Ahead?
CNCR has a Zacks ETF Rank #2 (Buy) with a High risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely still some promise for those who want to ride on this surging ETF a little longer.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on CNCR - FREE